272 related articles for article (PubMed ID: 34407821)
1. The cost burden of Crohn's disease and ulcerative colitis depending on biologic treatment status - a Danish register-based study.
Alulis S; Vadstrup K; Olsen J; Jørgensen TR; Qvist N; Munkholm P; Borsi A
BMC Health Serv Res; 2021 Aug; 21(1):836. PubMed ID: 34407821
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
[No Abstract] [Full Text] [Related]
3. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
[TBL] [Abstract][Full Text] [Related]
4. Societal costs attributable to Crohn's disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002-2016.
Vadstrup K; Alulis S; Borsi A; Elkjaer Stallknecht S; Nielsen A; Rikke Jørgensen T; Wennerström C; Qvist N; Munkholm P
Scand J Gastroenterol; 2020 Jan; 55(1):41-46. PubMed ID: 31960726
[No Abstract] [Full Text] [Related]
5. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
6. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
[TBL] [Abstract][Full Text] [Related]
7. Cost Burden of Crohn's Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis-A Danish Register-Based Study From 2003-2015.
Vadstrup K; Alulis S; Borsi A; Gustafsson N; Nielsen A; Wennerström ECM; Jørgensen TR; Qvist N; Munkholm P
Inflamm Bowel Dis; 2020 Aug; 26(9):1377-1382. PubMed ID: 31693731
[TBL] [Abstract][Full Text] [Related]
8. Increased use of biologics in the era of TNF-α inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based study from 2003-2016.
Qvist N; Vadstrup K; Alulis S; Borsi A; Munkholm P; Olsen J
Scand J Gastroenterol; 2021 May; 56(5):537-544. PubMed ID: 33736551
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
Zhao M; Lirhus S; Lördal M; Langholz E; Knudsen T; Voutilainen M; Høivik ML; Moum B; Anisdahl K; Saebø B; Haiko P; Malmgren C; Coskun M; Melberg HO; Burisch J
Aliment Pharmacol Ther; 2022 Sep; 56(6):989-1006. PubMed ID: 35902223
[TBL] [Abstract][Full Text] [Related]
10. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
Anisdahl K; Svatun Lirhus S; Medhus AW; Moum B; Melberg HO; Høivik ML
Scand J Gastroenterol; 2021 Oct; 56(10):1163-1168. PubMed ID: 34320885
[TBL] [Abstract][Full Text] [Related]
11. Less prevalent use of biologics for inflammatory bowel disease in patients from Non-Academic hospitals - a Danish register-based study of a region with 580,000 citizens.
Krarup AL; Larsen L; Nayeb AB; Grøntved S; Paaske Johnsen S; Esbjørn M; Fallingborg J; Nielsen GL; Allin K; Jess T; Olesen AE
Scand J Gastroenterol; 2023 May; 58(5):477-482. PubMed ID: 36356318
[TBL] [Abstract][Full Text] [Related]
12. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
14. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases.
Han M; Jung YS; Cheon JH; Park S
J Gastroenterol Hepatol; 2019 Jul; 34(7):1166-1174. PubMed ID: 30672608
[TBL] [Abstract][Full Text] [Related]
15. Trends and demographic patterns in biologic and corticosteroid prescriptions for inflammatory bowel disease: findings from electronic medical records, 2011-2020.
Xu F; Liu Y; Greenlund K; Carlson S
J Investig Med; 2022 Dec; 70(8):1771-1776. PubMed ID: 36455956
[TBL] [Abstract][Full Text] [Related]
16. Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies.
Cai Q; Ding Z; Fu AZ; Patel AA
BMC Gastroenterol; 2022 Dec; 22(1):545. PubMed ID: 36581802
[TBL] [Abstract][Full Text] [Related]
17. [ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN'S DISEASE)].
Veselov AV; Belousova EA; Bakulin IG; Uspenskiy YP; Dreval RO; Shkurko TV; Kashnikov BN; Fominykh YA; Knyazev OV; Romanov RI; Skalinskaia MI; Shipitsyn VV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2020 Oct; 28(Special Issue):1137-1145. PubMed ID: 33219771
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn's disease) in Spain: A Systematic Review.
Barreiro-de Acosta M; Molero A; Artime E; Díaz-Cerezo S; Lizán L; de Paz HD; Martín-Arranz MD
Adv Ther; 2023 May; 40(5):1975-2014. PubMed ID: 36928496
[TBL] [Abstract][Full Text] [Related]
19. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
20. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.
Park KT; Ehrlich OG; Allen JI; Meadows P; Szigethy EM; Henrichsen K; Kim SC; Lawton RC; Murphy SM; Regueiro M; Rubin DT; Engel-Nitz NM; Heller CA
Inflamm Bowel Dis; 2020 Jan; 26(1):1-10. PubMed ID: 31112238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
